Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis | Annals of the Rheumatic Diseases

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Archive
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Article info

Correspondence

Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis

Free

Authors

Motohisa Yamamoto Division of Rheumatology, Center for Antibody and Vaccine Therapy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan http://orcid.org/0000-0003-2742-2484PubMed articles Google scholar articles
Noritada Yoshikawa Division of Rheumatology, Center for Antibody and Vaccine Therapy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan PubMed articles Google scholar articles
Hirotoshi Tanaka Division of Rheumatology, Center for Antibody and Vaccine Therapy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan PubMed articles Google scholar articles

Correspondence to Dr Motohisa Yamamoto, Division of Rheumatology, Center for Antibody and Vaccine Therapy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 0608543, Japan; mocha@cocoa.plala.or.jp

Citation

Yamamoto M, Yoshikawa N, Tanaka H

Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis

Annals of the Rheumatic Diseases 2022;81:e50.

Publication history

Received January 31, 2020
Accepted January 31, 2020
First published February 7, 2020.

Online issue publication

May 04, 2023

Article Versions

Previous version (14 February 2022).
You are viewing the most recent version of this article.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.